4 completed, 4 terminated, 1 recruiting. 6 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 2 |
| Phase 2 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow patritumab: new trials by email Literature Review of patritumab trials Research Report on patritumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) Patritumab, Cetuximab, Cisplatin - Head and Neck Neoplasms | Phase 2 | Terminated | Daiichi Sankyo | 87 | 2015-12-22 | 2019-01-07 |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer Patritumab, Cetuximab, Cisplatin - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | Daiichi Sankyo | 15 | 2014-12-01 | 2018-09-11 |
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Patritumab, Erlotinib, Placebo - Lung Cancer, Non-small Cell Lung Cancer | Phase 3 | Terminated | Daiichi Sankyo | 145 | 2014-03-01 | 2018-01-23 |
| Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287) patritumab - Solid Tumors | Phase 1 | Completed | Daiichi Sankyo | 17 | 2013-06-01 | 2014-05-14 |
| Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors 64Cu-DOTA-U3-1287, U3-1287 (unlabeled) - Carcinoma, Sarcoma | Phase 1 | Terminated | Washington University School of Medicine | 12 | 2012-04-01 | 2013-12-20 |
| Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) U3-1287, Trastuzumab, Paclitaxel - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 29 | 2011-11-01 | 2017-10-18 |
| Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer U3-1287, Erlotinib, Placebo - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 222 | 2010-09-01 | 2021-06-16 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors U3-1287 (AMG888) - Advanced Solid Tumors | Phase 1 | Completed | U3 Pharma GmbH | 60 | 2008-08-01 | 2010-07-29 |
Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Bronchial Neoplasms (1) · Carcinoma, Squamous Cell (1) · Fibromatosis, Gingival, 2 (1) · Head and Neck Neoplasms (1) · Hemangiosarcoma (1) · Lethal Congenital Contracture Syndrome 2 (1) · Lung Diseases (1) · Lymphoma (1) · Neoplasm Metastasis (1)
Daiichi Sankyo (6) · QuantumLeap Healthcare Collaborative (1) · U3 Pharma GmbH (1) · Washington University School of Medicine (1)
United States (6) · United Kingdom (4) · Belgium (3) · Germany (3) · Hungary (3) · Italy (2) · Poland (2) · Romania (2) · Argentina (1) · Austria (1) · Bulgaria (1) · Canada (1) · Chile (1) · Czechia (1) · France (1)
A. Craig Lockhart, M.D. (1) · Kevin Harrington, Prof, MD (1) · Laura Esserman, MD, MBA (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23591447, PMID 26567113, PMID 27406346, PMID 27406347, PMID 28851423, PMID 31648099, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 36562609, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224
2014 (1), 2015 (1)